by admin | Apr 19, 2024 | Article
February 15, 2024 – Lupus Canada is honoured to be a member of the CIAN group. Together our goal is to protect more Canadians to improve the quality of life and significantly reduce hospitalization for vulnerable people. On page 60 of the Heal Canada Digital...
by admin | Nov 1, 2023 | Article
November 1, 2023 – We are pleased to announce that Lupus Canada has been selected as a funding recipient of the Government of Canada’s Community Services Recovery Fund which supports Community Service Organizations as they adapt for the long-term impacts of the...
by admin | Apr 19, 2023 | Article
Researcher Joan Wither, MD, PhD, FRCPC Research Proposal Abstract One of the major contributors to morbidity and mortality in Systemic Lupus Erythematosus is lupus nephritis (LN), which affects up to 65% of patients and which is characterized by...
by admin | Apr 19, 2023 | Article
The Lupus Foundation of America and Lupus Canada are pleased to announce Joan Wither, MD, PhD, FRCPC has been awarded the 2023 Lupus Canada Catalyst Award for her study “Interferon and Prediction of Treatment Responses in Lupus Nephritis,” focused on interferon...
by admin | Apr 19, 2023 | Article
November 30, 2023 – Lupus Canada is pleased to share that Anifrolumab (Saphnelo) will be included on the Alberta Drug Benefit List effective December 1st, 2023. For details regarding this listing and renewal criteria, please visit the Alberta Drug Benefit...
